CN116763906A - Dendritic tumor vaccine cultivation technology - Google Patents
Dendritic tumor vaccine cultivation technology Download PDFInfo
- Publication number
- CN116763906A CN116763906A CN202111049791.3A CN202111049791A CN116763906A CN 116763906 A CN116763906 A CN 116763906A CN 202111049791 A CN202111049791 A CN 202111049791A CN 116763906 A CN116763906 A CN 116763906A
- Authority
- CN
- China
- Prior art keywords
- tumor vaccine
- tumor
- technology
- vaccine
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 41
- 229960005486 vaccine Drugs 0.000 title claims abstract description 29
- 238000005516 engineering process Methods 0.000 title claims abstract description 15
- 108090000695 Cytokines Proteins 0.000 claims abstract description 10
- 102000004127 Cytokines Human genes 0.000 claims abstract description 10
- 230000006698 induction Effects 0.000 claims abstract description 10
- 238000000338 in vitro Methods 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000000427 antigen Substances 0.000 claims abstract description 7
- 108091007433 antigens Proteins 0.000 claims abstract description 7
- 102000036639 antigens Human genes 0.000 claims abstract description 7
- 210000004369 blood Anatomy 0.000 claims abstract description 7
- 239000008280 blood Substances 0.000 claims abstract description 7
- 230000002093 peripheral effect Effects 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 6
- 210000001787 dendrite Anatomy 0.000 claims abstract description 4
- 229920001184 polypeptide Polymers 0.000 claims abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 3
- 210000005087 mononuclear cell Anatomy 0.000 claims description 3
- 238000002255 vaccination Methods 0.000 abstract description 2
- 238000012258 culturing Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000035772 mutation Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000037125 natural defense Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a dendritic tumor vaccine cultivating technology, which comprises (1) collecting peripheral venous blood about 30ml, and culturing in vitro for 7 days to obtain 1-5 x10 6 The dendrites are thin; (2) Selecting humanized cytokines for in vitro induction preparation; (3) The tumor vaccine with high maturity and powerful activity and specificity may be obtained through tumor polypeptide antigen loading technology. The preparation process can prepare the highly mature tumor vaccine, and the duration of the immune protection effect on the organism after the vaccination is long, so that the organism can be prevented from being affected by corresponding tumors within 10 years. The vaccine has the advantages of wide application range, simple preparation method, convenient operation and popularization and application suggestion.
Description
Technical Field
The invention relates to the field of vaccine cultivation, in particular to a dendritic tumor vaccine cultivation technology.
Background
The human immune system is generally capable of recognizing and combating cancer cells. However, this capability is often inadequate and cancer continues to spread. Cancer immunotherapy is based on the use and enhancement of the ability of the immune system to combat cancer.
Although some vaccines for treating cancers exist in the prior art, the application range of the vaccines is relatively single, and the requirements of people on vaccine cultivation are gradually met.
Therefore, a technology for cultivating dendritic tumor vaccine is a problem to be solved in the whole society.
Disclosure of Invention
In order to solve the technical problems, the technical scheme provided by the invention is as follows: a technology for cultivating dendritic tumor vaccine comprises the following cultivation techniques,
(1) Collecting peripheral venous blood about 30ml, and performing in vitro induction culture for 7 days to obtain 1-5 x10 6 The dendrites are thin;
(2) Selecting humanized cytokines for in vitro induction preparation;
(3) The tumor vaccine with high maturity and powerful activity and specificity may be obtained through tumor polypeptide antigen loading technology.
Further, the humanized cytokine in the step (2) is a GMP-grade humanized cytokine.
Further, after about 30ml of peripheral venous blood is collected in the step (1), mononuclear cells are separated and extracted for induction.
Compared with the prior art, the invention has the advantages that: the preparation process can prepare the highly mature tumor vaccine, and the duration of the immune protection effect on the organism after the vaccination is long, so that the organism can be prevented from being affected by corresponding tumors within 10 years. The vaccine has the advantages of wide application range, simple preparation method, convenient operation and popularization and application suggestion.
Drawings
FIG. 1 is an immunofluorescent staining chart of a DC cell maturation marker molecule and actin of a dendritic tumor vaccine implantation technique of the present invention;
FIG. 2 is a flow chart of DC cell phenotypes cultured for 5-7 days;
FIG. 3 is a statistical plot of DC cell phenotypes cultured to 7 days.
Detailed Description
The present invention will be described in further detail with reference to the accompanying drawings.
The present invention will be described in detail with reference to the accompanying drawings.
The invention provides a dendritic tumor vaccine cultivating technology when in specific implementation, which comprises the following cultivating technology,
(1) Collecting peripheral venous blood about 30ml, and performing in vitro induction culture for 7 days to obtain 1-5 x10 6 The dendrites are thin;
(2) Selecting humanized cytokines for in vitro induction preparation;
(3) The tumor vaccine with high maturity and powerful activity and specificity may be obtained through tumor polypeptide antigen loading technology.
As a further illustration of the invention, the humanized cytokine in step (2) is a GMP-grade humanized cytokine.
As a further illustration of the present invention, the step (1) is performed by collecting about 30ml of peripheral venous blood, and then isolating and extracting mononuclear cells for induction.
As a further explanation of the invention, it is now possible to load more than 150+ specific broad-spectrum tumor antigens in addition to tumor antigen loads of non-solid tumors of leukemia; the neotumor antigen stimulates the natural defenses of human body by recognizing the specific mutation of each tumor, thereby pertinently destroying cancer cells. The vaccine can trigger the human immune system to recognize the tumor through the unique mutation of the tumor, thereby effectively preventing various cancers.
More importantly, unlike traditional chemotherapy, vaccines selectively destroy tumor cells by using the natural defense system of the human body, with limited damage to healthy cells.
As a further illustration of the present invention, we use a number of predicted new drugs for personalized cancer vaccines. The manufacturing process involves several steps. Tumor biopsies and healthy tissue (e.g., peripheral blood cells) of patients diagnosed with cancer are examined by NGS. Tumor-specific mutations in the protein-encoding genes are then identified by comparing tumor sequences to normal, healthy DNA. The calculation tool classifies these mutations to obtain the highest immunogenicity potential, i.e. for predicting the expression and binding affinity of the novel isobars for HLA molecules.
We can address a broad range of cancer entities alone, for example:
melanoma, lung cancer (NSCLC), breast cancer, colon cancer, prostate cancer, esophageal cancer, ovarian cancer, cervical cancer, head and neck cancer, gastric cancer, pancreatic cancer, melanoma, glioblastoma, renal cancer, hepatocellular carcinoma (HCC), soft tissue, osteosarcoma, and the like.
The efficacy of the mutant vaccine is as follows:
survival of patients treated with anti-tumor vaccine
Among the multiple MHC alleles, 93.3% of patients observed an immune response elicited by the vaccine. Three years of no progress and no mortality were 0.63 and 0.84, respectively, and immunoreactive patients showed a two year no progress of 0.82.
The tumor vaccine can inhibit lung cancer, gastric cancer, liver cancer, colon cancer, rectal cancer, esophagus cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma, brain tumor, nasopharyngeal carcinoma, skin cancer, bone tumor, renal cancer, prostatic cancer, breast cancer, cervical cancer and other fields.
The invention and its embodiments have been described above with no limitation, and the actual construction is not limited to the embodiments of the invention as shown in the drawings. In summary, if one of ordinary skill in the art is informed by this disclosure, a structural manner and an embodiment similar to the technical solution should not be creatively devised without departing from the gist of the present invention.
Claims (3)
1. A technology for cultivating dendritic tumor vaccine is characterized in that: comprises the following cultivation techniques which are adopted,
(1) Collecting peripheral venous blood about 30ml, and performing in vitro induction culture for 7 days to obtain 1-5 x10 6 The dendrites are thin;
(2) Selecting humanized cytokines for in vitro induction preparation;
(3) The tumor vaccine with high maturity and powerful activity and specificity may be obtained through tumor polypeptide antigen loading technology.
2. The technology for cultivating a dendritic tumor vaccine according to claim 1, wherein: the humanized cytokine in the step (2) is a GMP-grade humanized cytokine.
3. The technology for cultivating a dendritic tumor vaccine according to claim 1, wherein: after about 30ml of peripheral venous blood is collected in the step (1), mononuclear cells are separated and extracted for induction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111049791.3A CN116763906A (en) | 2021-09-08 | 2021-09-08 | Dendritic tumor vaccine cultivation technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111049791.3A CN116763906A (en) | 2021-09-08 | 2021-09-08 | Dendritic tumor vaccine cultivation technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116763906A true CN116763906A (en) | 2023-09-19 |
Family
ID=87988209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111049791.3A Pending CN116763906A (en) | 2021-09-08 | 2021-09-08 | Dendritic tumor vaccine cultivation technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116763906A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001181205A (en) * | 1999-11-12 | 2001-07-03 | Jiu Ri | Method for producing tumor-specific anti-tumor cellular vaccine using dendritic cell and tumor cell |
| KR20030084826A (en) * | 2003-09-30 | 2003-11-01 | 국립암센터 | Dendritic cell pulsing allogeneic tumor-associated antigen, method for the preparation thereof and vaccine composition containing same for treating cancer |
| CN102600462A (en) * | 2012-03-29 | 2012-07-25 | 戚春建 | Human dendritic cell tumor vaccine, preparation and application thereof |
| CN102600467A (en) * | 2012-03-29 | 2012-07-25 | 戚春建 | Application of beta-dextran in preparation of human dendritic cell tumor vaccine |
| CN111375054A (en) * | 2018-12-27 | 2020-07-07 | 复旦大学附属肿瘤医院 | Tumor vaccine composition, and preparation method and application thereof |
-
2021
- 2021-09-08 CN CN202111049791.3A patent/CN116763906A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001181205A (en) * | 1999-11-12 | 2001-07-03 | Jiu Ri | Method for producing tumor-specific anti-tumor cellular vaccine using dendritic cell and tumor cell |
| KR20030084826A (en) * | 2003-09-30 | 2003-11-01 | 국립암센터 | Dendritic cell pulsing allogeneic tumor-associated antigen, method for the preparation thereof and vaccine composition containing same for treating cancer |
| CN102600462A (en) * | 2012-03-29 | 2012-07-25 | 戚春建 | Human dendritic cell tumor vaccine, preparation and application thereof |
| CN102600467A (en) * | 2012-03-29 | 2012-07-25 | 戚春建 | Application of beta-dextran in preparation of human dendritic cell tumor vaccine |
| CN111375054A (en) * | 2018-12-27 | 2020-07-07 | 复旦大学附属肿瘤医院 | Tumor vaccine composition, and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 翟妍;张震宇;王淑珍;乔宝丽;: "肿瘤细胞裂解物致敏的树突状细胞用于大鼠卵巢上皮癌免疫预防的体内研究", 中国妇幼保健, no. 13, pages 1850 - 1852 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500006A5 (en) | ||
| CN100591762C (en) | Antigen presenting cells, method for their preparation and their use for cancer vaccines | |
| US6228640B1 (en) | Programmable antigen presenting cell of CD34 lineage | |
| CN105039269A (en) | Novel viral vaccine for treating non-small cell lung cancer and preparation method thereof | |
| CN109073637A (en) | For predicting the method for protein or protein fragments for the serviceability of immunization therapy | |
| CN102727524A (en) | Application of CIK (cytokine induced killer) cell loaded by anti-CD3/anti-CD133 bispecific antibody | |
| CN103555762B (en) | AFP and GM-CSF dual-gene co-expression recombinant vector as well as preparation method and application of recombinant vector | |
| US6977073B1 (en) | Method for stimulating an immune response | |
| CN103614414A (en) | AFP (Alpha Fetoprotein) and IL-2 (Interleukin-2) double-gene co-expressing recombinant vector as well as preparation method and application thereof | |
| CN106957822B (en) | Culture method, kit and application of in-vitro amplified gene editing activated T cells | |
| CN116763906A (en) | Dendritic tumor vaccine cultivation technology | |
| Glick et al. | DNA-induced pigment production in a hamster cell line | |
| US20110206735A1 (en) | Tumorigenic CancerStemCells, Methods of Isolating and Using the Same | |
| CN1416896A (en) | Tumor CT antigen immune inducing agent for treating liver cancer and its prepn | |
| CN108467855B (en) | Novel lung-specific metastatic hepatoma cell and preparation thereof | |
| CN106117338B (en) | HLA-A0201-restricted CTL epitope of cytokeratin 19 | |
| CN106117334B (en) | CTL recognition epitope peptide of tumor antigen MAGE3 and application thereof | |
| CN110205307A (en) | The recombination the Temple of Heaven strain oncolytic vaccinia virus of removal VGF gene and preparation and application | |
| CN113069547B (en) | Application of Bap1 as tumor treatment target in preparation of drugs for preventing or treating tumors | |
| CN107188959B (en) | Antigenic peptide T790M-6 and application thereof in preparation of medicines for treating non-small cell lung cancer | |
| Strohal et al. | T-cell receptor repertoire of lymphocytes infiltrating cutaneous melanoma is predominated by Vα specificities present in T-cells of normal human skin | |
| CN104928253B (en) | A kind of tumour cell and its construction method of antigenicity enhancing | |
| CN101805724B (en) | Targeting WWOX (WW domain-containing oxidoreductase) gene recombinant adenovirus and preparation method and application thereof | |
| WO2022198611A1 (en) | Car chimeric antigen receptor sequence and car-nk cells applying same | |
| CN108467854B (en) | Novel bone-specific metastatic hepatoma cell and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |